Table 1.
Demographic characteristics of 49 patients after LT
| Factors | Median or number | Mean ± SD | Range |
|---|---|---|---|
| General information | |||
| Recipient age (y) | 54.5 | 53.0 ± 9.7 | 28.1–69.8 |
| Recipient gender, male | 42 (85.7%) | ||
| Recipient CMV IgG, positive | 49 (100.0%) | ||
| Donor age (y) | 31.1 | 32.6 ± 10.7 | 18.5–59.7 |
| Donor gender, male | 24 (49.0%) | ||
| Donor CMV IgG, positive | 41 (83.7%) | ||
| MELD score | 14 | 16.3 ± 8.7 | 8–40 |
| HBV infection | 24 (49.0%) | ||
| HCV infection | 12 (24.5%) | ||
| Alcohol use | 21 (42.9%) | ||
| HCC | 23 (46.9%) | ||
| Ascites (ml) | 900 | 3,238.4 ± 5,550.3 | 0–28,800 |
| LDLT | 47 (95.9%) | ||
| Right lobe grafta | 43 (91.5%) | ||
| GRWR, %a | 0.90 | 0.95 ± 0.21 | 0.61–1.52 |
| PP65 antigenemia, positive | 22 (44.9%) | ||
| PP65, maximum/per 500,000 leukocytes | 0.0 | 1.9 ± 4.0 | 0–23 |
| CMV Viremia, positive | 29 (59.2%) | ||
| CMV qPCR, maximum copies/ml | 150 | 231.4 ± 432.6 | 0–2,243 |
| Clinical outcomes | |||
| Follow‐up period (mo) | 28.5 | 27.6 ± 9.9 | 1.0–42.9 |
| Two‐year mortality, cases | 6 (12.2%) | ||
| Major post‐transplant complication | 4 (8.2%) | ||
| Ventilator dependence, days | 1 | 3.4 ± 8.5 | 1–49 |
| Posttransplant ICU stay, days | 11 | 14.1 ± 8.0 | 6–49 |
| Posttransplant hospitalization, days | 28 | 37.3 ± 34.4 | 21–250 |
Abbreviations: CMV, cytomegalovirus; GRWR, graft recipient weight ratio; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ICU, intense care unit; LDLT, living donor liver transplantation; MELD, model for end‐stage liver disease; qPCR, quantitative polymerase chain reaction; SD, standard deviation.
a
Only calculated from LDLT cases.